Stocks
Black Diamond Therapeutics Financial Statements (BDTX) |
||||||||||
| Black Diamond Therapeuticssmart-lab.ru | % | 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 09.05.2023 | 11.08.2023 | 06.11.2023 | 12.03.2024 | 09.05.2024 | 09.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 0.000 | 0.000 | 0.000 | 4.89 | 0.000 | 4.89 | |||
| Operating Income, bln rub | -21.6 | -20.0 | -24.0 | -20.9 | -20.2 | -85.1 | ||||
| EBITDA, bln rub | ? | -21.6 | -19.9 | -24.0 | -20.8 | -20.2 | -84.9 | |||
| Net profit, bln rub | ? | -20.2 | -19.2 | -23.0 | -19.4 | -18.2 | -79.8 | |||
| OCF, bln rub | ? | -20.0 | -14.4 | -18.4 | -14.0 | -21.2 | -67.9 | |||
| CAPEX, bln rub | ? | 0.000 | 0.000 | 0.033 | 0.033 | 0.000 | 0.066 | |||
| FCF, bln rub | ? | -20.0 | -14.4 | -18.4 | -13.9 | -21.2 | -67.9 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 21.6 | 20.0 | 24.0 | 20.8 | 20.2 | 85.0 | ||||
| Cost of production, bln rub | 0.812 | 0.812 | 0.823 | 0.086 | 0.086 | 1.81 | ||||
| R&D, bln rub | 14.8 | 13.2 | 16.2 | 15.2 | 13.5 | 58.0 | ||||
| Interest expenses, bln rub | 0.686 | 0.000 | 0.000 | 0.686 | 0.000 | 0.686 | ||||
| Assets, bln rub | 135.6 | 119.9 | 172.4 | 158.6 | 142.5 | 142.5 | ||||
| Net Assets, bln rub | ? | -355.9 | 82.2 | 134.3 | 116.7 | 104.3 | 104.3 | |||
| Debt, bln rub | 27.5 | 26.8 | 26.0 | 25.3 | 24.5 | 24.5 | ||||
| Cash, bln rub | 103.4 | 89.5 | 144.3 | 131.4 | 115.2 | 115.2 | ||||
| Net debt, bln rub | -75.9 | -62.8 | -118.2 | -106.1 | -90.7 | -90.7 | ||||
| Ordinary share price, rub | 1.89 | 5.05 | 2.87 | 2.81 | 5.07 | 1.80 | ||||
| Number of ordinary shares, mln | 36.5 | 36.5 | 50.9 | 51.6 | 51.8 | 51.8 | ||||
| Market cap, bln rub | 69 | 184 | 146 | 145 | 263 | 93 | ||||
| EV, bln rub | ? | -7 | 122 | 28 | 39 | 172 | 3 | |||
| Book value, bln rub | -356 | 82 | 134 | 117 | 104 | 104 | ||||
| EPS, rub | ? | -0.55 | -0.52 | -0.45 | -0.38 | -0.35 | -1.54 | |||
| FCF/share, rub | -0.55 | -0.39 | -0.36 | -0.27 | -0.41 | -1.31 | ||||
| BV/share, rub | -9.75 | 2.25 | 2.64 | 2.26 | 2.01 | 2.01 | ||||
| EBITDA margin, % | ? | -424.4% | -1 734% | |||||||
| Net margin, % | ? | -396.6% | -1 630% | |||||||
| FCF yield, % | ? | -110.9% | -39.4% | -51.0% | -46.0% | -25.8% | -72.8% | |||
| ROE, % | ? | 22.5% | -93.7% | -59.1% | -70.0% | -76.5% | -76.5% | |||
| ROA, % | ? | -59.1% | -64.2% | -46.1% | -51.6% | -56.0% | -56.0% | |||
| P/E | ? | -0.86 | -2.39 | -1.84 | -1.77 | -3.29 | -1.17 | |||
| P/FCF | -0.90 | -2.54 | -1.96 | -2.17 | -3.87 | -1.37 | ||||
| P/S | ? | 29.6 | 53.7 | 19.1 | ||||||
| P/BV | ? | -0.19 | 2.24 | 1.09 | 1.24 | 2.52 | 0.89 | |||
| EV/EBITDA | ? | 0.08 | -1.39 | -0.31 | -0.45 | -2.03 | -0.03 | |||
| Debt/EBITDA | 0.84 | 0.72 | 1.32 | 1.23 | 1.07 | 1.07 | ||||
| R&D/CAPEX, % | 48 952% | 46 070% | 87 833% | |||||||
| CAPEX/Revenue, % | 0.67% | 1.35% | ||||||||
| Black Diamond Therapeutics shareholders | ||||||||||
